|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.59 AUD | +1.11% |
|
-4.14% | +30.18% |
Business description: Telix Pharmaceuticals Limited
Number of employees: 1,152
Sales by Activity: Telix Pharmaceuticals Limited
| Fiscal Period: December | 2021 (AUD) | 2022 (AUD) | 2023 (AUD) | 2024 (AUD) | 2025 (USD) |
|---|---|---|---|---|---|
Precision Medicine | - | - | - | 771M | 622M |
Manufacturing Solutions | - | - | - | 2.75M | 245M |
Therapeutics | - | - | - | 9.35M | 9.27M |
Product Development | - | 3.73M | 5.5M | - | - |
Commercial | - | 156M | 497M | - | - |
Pharmaceuticals | 7.6M | - | - | - | - |
Inter-Segment Elimination | - | - | - | - | -72.51M |
Geographical breakdown of sales: Telix Pharmaceuticals Limited
| Fiscal Period: December | 2021 (AUD) | 2022 (AUD) | 2023 (AUD) | 2024 (AUD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | - | 150M | 490M | 762M | 785M |
China | - | 3.35M | 5.29M | - | 9.83M |
Other Countries | - | 2.5M | 4.67M | 16.01M | 9.06M |
Canada | - | - | - | 2.54M | - |
United Kingdom | - | 2.04M | 1.31M | 579K | - |
Belgium | - | 564K | 458K | 546K | - |
Austria | - | 1.48M | - | - | - |
Australia | 7.6M | 149K | 1.17M | 1.22M | - |
Executive Committee: Telix Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 02/01/2017 | |
Darren Smith
DFI | Director of Finance/CFO | 60 | 30/07/2022 |
| Chief Tech/Sci/R&D Officer | - | - | |
David Cade
CTO | Chief Tech/Sci/R&D Officer | 57 | 31/12/2023 |
Craig Ulrick
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2022 |
Composition of the Board of Directors: Telix Pharmaceuticals Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 02/01/2017 | |
Mark Nelson
CHM | Chairman | 66 | 02/02/2026 |
Jann Skinner
BRD | Director/Board Member | 68 | 18/06/2018 |
Marie McDonald
BRD | Director/Board Member | 70 | 02/03/2025 |
Holdings: Telix Pharmaceuticals Limited
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,918,112 | 0.57% | 21 M $ |
Company details: Telix Pharmaceuticals Limited
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.11% | -4.14% | -42.51% | +31.71% | 3.68B | |
| -0.77% | -2.47% | -16.97% | -16.79% | 43.3B | |
| +1.39% | +5.91% | +35.08% | +32.18% | 34.55B | |
| +1.09% | -1.01% | +247.95% | +463.28% | 30.65B | |
| +0.87% | -0.77% | +12.12% | -6.97% | 28.97B | |
| +1.05% | -2.28% | +32.43% | +26.70% | 27.29B | |
| -0.43% | +5.49% | - | - | 14.82B | |
| -3.59% | -3.37% | +113.03% | +4,035.93% | 13.51B | |
| +0.60% | +0.77% | +126.16% | +113.55% | 12.46B | |
| +1.16% | +0.78% | +5.45% | -1.33% | 12.13B | |
| Average | +0.24% | +0.08% | +56.97% | +519.80% | 22.14B | |
| Weighted average by Cap. | +0.33% | +0.59% | +59.66% | +344.58% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TLX Stock
- Company Telix Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition